CN100340266C - Jiangzhi capsule good for liver and its preparing process - Google Patents
Jiangzhi capsule good for liver and its preparing process Download PDFInfo
- Publication number
- CN100340266C CN100340266C CNB2004100977959A CN200410097795A CN100340266C CN 100340266 C CN100340266 C CN 100340266C CN B2004100977959 A CNB2004100977959 A CN B2004100977959A CN 200410097795 A CN200410097795 A CN 200410097795A CN 100340266 C CN100340266 C CN 100340266C
- Authority
- CN
- China
- Prior art keywords
- liver
- ganoderma
- blood
- drying
- tremella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 10
- 230000008569 process Effects 0.000 title claims abstract description 5
- 210000004185 liver Anatomy 0.000 title abstract description 31
- 239000009427 jiangzhi Substances 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 claims abstract description 55
- 239000008280 blood Substances 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 241000222336 Ganoderma Species 0.000 claims abstract description 20
- 241001506047 Tremella Species 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 6
- 229920001353 Dextrin Polymers 0.000 claims abstract description 4
- 239000004375 Dextrin Substances 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 4
- 235000019425 dextrin Nutrition 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 235000015424 sodium Nutrition 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 17
- 238000001694 spray drying Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 239000012567 medical material Substances 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 7
- 241001614291 Anoplistes Species 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 13
- 230000036541 health Effects 0.000 abstract description 12
- 238000009835 boiling Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 4
- 244000233890 Alisma plantago Species 0.000 abstract 2
- 235000017300 Alisma plantago Nutrition 0.000 abstract 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 2
- 241000830535 Ligustrum lucidum Species 0.000 abstract 2
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 238000005507 spraying Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 16
- 230000000144 pharmacologic effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 201000005577 familial hyperlipidemia Diseases 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000002443 hepatoprotective effect Effects 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 4
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 4
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Jiangzhi capsule good for liver and a preparing process. The Jiangzhi capsule prepared from ganoderma, red sage root, barbary wolfberry fruit, gynostemma pentaphylla, glossy privet fruit, water plantain, tremella, etc. is a traditional Chinese medicine which organically combines the two health care functions of protecting liver and regulating blood fat. The present invention comprises the following preparation processes that ganoderma, red sage root, barbary wolfberry fruit, gynostemma pentaphylla, glossy privet fruit, water plantain and tremella are dynamically extracted under a sub-boiling state, finely filtered by micropores, concentrated under vacuum and dried by spraying so as to obtain powder; then, the powder is added with carboxymethyl starch sodium, starch, dextrin, etc. so as to be mixed, dried, granulated, encapsulated and subpackaged so that the capsules are obtained. The preparation process integrates various advanced technologies; compared with the traditional preparation process, the production period of the present invention is shortened by one half, and the present invention has the functions of saving energy, protecting environment, improving labor intensity and quality of products, etc.
Description
Technical field
The present invention relates to the health food technology field of hepatoprotective and blood lipid regulation, especially relating to a kind of is the blood fat reducing liver-benefiting capsules and preparation method thereof of raw material with the Chinese medicine medicine.
Background technology
Along with China's rapid economic development, the raising of national life level, the adjustment of dietary structure, excessive consumption of alcohol and because in the food excessive albumen, lipid, saccharide to take in the disease and the potential hazard that bring more and more serious, as alcoholic liver, fatty liver, medicine liver etc.The patient of these diseases is more and more with relevant sub-health population, according to statistics, the pathogenesis of fatty liver rate has reached 10%, the alcoholic liver sickness rate has reached 1.92%, hyperlipidemia then is 3.84%, because chemical liver injury and hyperlipidemia to liver that factors such as ethanol, medicine, environmental pollution cause become a harm greatly that hinders people healthy.
Though the health food of some hepatoprotective and the medicine of some treatment hepatitis are also arranged at present, and these health foods and medicine exist many deficiencies.They are not strong to the health care of the chemical liver injury of liver, do not have the health care of blood lipid regulation exactly, and medicine and be not suitable for the situation that non-hepatitis is taken for a long time can not be applicable to for a long time and take.Disclosed a kind of medicine for the treatment of chronic hepatopathy of Chinese patent CN1243743 (2000) and preparation method thereof for example, it is a treatment hepatic fibrosis effect new Chinese medicine preferably, but owing to be medicine, constituent content wherein is not suitable for taking for a long time that people keep healthy and need.All these are difficult to satisfy the healthy health care needs of people.Exploitation in conjunction with the health food of hepatoprotective and two kinds of health cares of blood lipid regulation is very urgent.
Summary of the invention
The invention provides a kind of blood fat reducing liver-benefiting capsules and preparation method thereof.
The present invention is according to the theoretical health food that proposes of traditional Chinese medicine theory and health care, is to be raw materials of effective components with Ganoderma, Radix Salviae Miltiorrhizae, Fructus Lycii, Herb Gynostemmae Pentaphylli, Fructus Ligustri Lucidi, Rhizoma Alismatis, Tremella.
Blood fat reducing liver-benefiting capsules component of the present invention and weight portion content thereof are as follows:
Ganoderma 17.64～26.46g, Radix Salviae Miltiorrhizae 17.64～26.46g, Fructus Lycii 11.76～17.64g, Herb Gynostemmae Pentaphylli 11.76～17.64g, Fructus Ligustri Lucidi 11.76～17.64g, Rhizoma Alismatis 17.64～26.46g, Tremella 11.76～7.64g.
The prescription of blood fat reducing liver-benefiting capsules of the present invention is formed foundation: theory of Chinese medical science thinks that fatty liver is that dampness-heat of the liver pents up, and the suffocating of liver and gall imbalance causes in the phlegm-damp gives birth to qi depression to blood stasis; Stasis of blood heat-transformation of a specified duration causes taste, and expectorant heat is stopped up Sheng: injure one's stomach and kidney for a long time, cause hepatic and renal YIN deficiency.Alcoholic liver injury is to accumulate in the damp and hot alcoholism to cause liver and lose bar and reach, dysfunction of the spleen in transportation, and phlegm-damp stasis of blood knot hinders in the liver network and forms.Should use depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, invigorating qi and benefiting blood, the method for dissipating phlegm and resolving masses.
The present invention carries out prescription according to the above-mentioned Chinese medical discrimination rule of treatment, is made up of Ganoderma, Radix Salviae Miltiorrhizae, Fructus Lycii, Herb Gynostemmae Pentaphylli, Fructus Ligustri Lucidi, Rhizoma Alismatis, Tremella etc., has the health care of blood lipid regulation, protection chemical liver injury.The present invention is according to the theory of Chinese medicine and pharmacy, and with Ganoderma, Radix Salviae Miltiorrhizae benefiting QI for activating blood circulation, transferring the fat hepatoprotective is monarch drug, the Shennong's Herbal meaning: " clothes are made light of one's life by commiting suicide and prolonged life for a long time for Ganoderma, QI invigorating tonifying liver ".Radix Salviae Miltiorrhizae " is controlled blood and is nourished blood, fall and promoting the circulation of blood ".Modern pharmacological research proves that Ganoderma, Radix Salviae Miltiorrhizae all have the effect of blood lipid regulation preferably, can alleviate the liver tissue injury that carbon tetrachloride causes, promotes liver cell regeneration.Fructus Lycii, the Fructus Ligustri Lucidi nourishing the liver and kidney that all can nourish blood, two medicine principal drug assistances are to be ministerial drug with the merit of the tonifying liver of strengthening nourishing blood, modern study shows, the Fructus Lycii master contains lycium barbarum polysaccharide, and Fructus Ligustri Lucidi contains effective ingredient such as oleanolic acid, Palmic acid, and pharmacological action such as blood fat reducing, hepatoprotective is preferably all arranged.
The Rhizoma Alismatis eliminating dampness and diuresis; the Herb Gynostemmae Pentaphylli invigorating the spleen and benefiting QI, detoxification and promoting urination, the nourishing the liver of Tremella YIN nourishing; eutrophy again; three medicines are for assistant makes it product, and modern pharmacological research shows that Rhizoma Alismatis, Herb Gynostemmae Pentaphylli, Tremella be the energy blood lipid regulation all; blood viscosity lowering; the double detoxification ability that can improve liver can alleviate the damage of chemicals to hepatic tissue, the liver protecting function.All medicines share, and full side can blood lipid regulation, and the health-care effect of protection chemical liver injury is arranged again.
Ganoderma, nature and flavor are sweet flat, go into the Liver and kidney warp, function QI invigorating tonify deficiency, nourishing the liver is calmed the nerves, and Fructus Alpiniae Oxyphyllae is intelligent.Its main component contains triterpenes and ganoderan.Modern pharmacological research proves that this product has blood pressure lowering, blood fat reducing, protects the liver and improve pharmacological actions such as memory, enhancing immunity.
Radix Salviae Miltiorrhizae, the nature and flavor hardship is slightly cold, and goes into the conscience warp, function blood circulation promoting and blood stasis dispelling, clearing away heart-fire for tranquillization.Its main component contains TANSHINONES, danshensu etc.Modern pharmacological research proves that this product can alleviate the liver tissue injury that carbon tetrachloride causes, promotes liver cell regeneration, effects such as cholesterol reducing.
Fructus Lycii, nature and flavor are sweet flat, go into the Liver and kidney warp, the function invigorating the liver and kidney of nourishing blood, lung moistening makes eye bright.Main component contains trace element such as betanin, polysaccharide and calcium, zinc.Modern pharmacological research proves that this product extractum has blood sugar lowering, blood lipid regulation effect, and lycium barbarum polysaccharide has hepatoprotective effect.
Fructus Ligustri Lucidi, the Liver and kidney warp is gone in the cold of nature and flavor sweetness and bitterness, the function invigorating the liver and kidney, crow must make eye bright.Main component contains oleanolic acid, mannitol, glucose, Palmic acid, stearic acid, oleic acid, glyceric acid etc.Modern pharmacological research proves that this product has pharmacological actions such as blood fat reducing, blood glucose, hepatoprotective.
Rhizoma Alismatis, the property slightly sweet flavor is cold, returns kidney channel, and the function promoting diuresis to eliminate damp pathogen expels the heat-evil.Main component contains alisol and daucosterol etc.Modern pharmacological research proves that this product has pharmacological actions such as blood fat reducing, cholesterol reducing, anti-fatty liver, fat-reducing.
Tremella, nature and flavor are sweet flat, the nourishing the liver of function YIN nourishing, the lung moistening and production of body fluid promoting, main component contains tremella polysaccharide etc.Modern pharmacological research proves that this product energy blood lipid regulation promotes hepatocellular metabolism, improves pharmacological actions such as liver detoxification ability.
Herb Gynostemmae Pentaphylli, nature and flavor are sweet flat, go into spleen channel, the function invigorating the spleen and benefiting QI.Main component contains saponin, flavonoid and aminoacid etc.Modern pharmacological research proves that this product has pharmacological actions such as defying age, antioxidation, blood lipid regulation, hepatoprotective, anti-fatty liver, anti-hepatic fibrosis.
Recipe ingredient of the present invention, its dosage is to be foundation with tradition each component modern pharmacology and clinical research in proved recipe and prescription, and the consumption of reference treatment senile disease and defying age body-building again is by repeatedly prescription test, overall merit and decide the dosage of active component as shown in table 1 below.
The consumption reference value of active component and the dosage of Comprehensive Assessment in table 1. prescription
Obviously, active component dosage is purpose with the health body-building all in the prescription, is starkly lower than the Drug therapy consumption.
Another problem of the present invention solves like this, a kind of preparation blood fat reducing liver-benefiting capsules method is provided, comprise extraction filtration, vacuum concentration, spray drying, the particulate preparation and dry, encapsulated and packing, control of product quality processing step of preparation raw material, medical material, it is characterized in that: (1) preparation raw material: by Ganoderma 17.64～26.46g, Radix Salviae Miltiorrhizae 17.64～26.46g, Fructus Lycii 11.76～17.64g, Herb Gynostemmae Pentaphylli 11.76～17.64g, Fructus Ligustri Lucidi 11.76～17.64g, Rhizoma Alismatis 17.64～26.46g, conduct preparation raw material after the prescription weighing of Tremella 11.76～7.64g; (2) extraction of medical material, filtration: get formula ratio and (separately Ganoderma is added 8 times of water gaging Asias boil dynamic extraction three times, each 1.5 hours, merge and filter, concentrate the back spray drying, Radix Salviae Miltiorrhizae adds 8 times of water gaging Asias boil dynamic extraction three times, each 1 hour, merge and filter, concentrate the back spray drying, then with Ganoderma, Radix Salviae Miltiorrhizae xeraphium and other Chinese medical concrete powder mixings) medical material, put in the multi-function extractor, add the about 30min of water logging bubble of 8 times of medical material amounts, boil dynamic extraction 3 times of employing Asia, each each 1.5 hours, micropore fine filtration is collected filtrate, puts in the clean container and preserves; (3) vacuum concentration: get above-mentioned filtrate, putting and being concentrated into relative density in the vacuum concentrator is 1.05-1.10 (60 ℃ heat survey), and concentrated solution is put in the clean container and preserved, the vacuum concentration process parameter: vacuum is 0.04Mpa, temperature＜80 ℃; (4) spray drying: get vacuum concentration liquid, adopt the G-15 spray drying, make material obtain drying in moment, dry extract is put in the clean container and is preserved, drying parameter: 180 ℃ of intake air temperatures, 60 ℃ of air outlet temperature, 4 seconds drying times; (5) particulate preparation is with dry: get above-mentioned Chinese crude drug extract dry extract, add carboxymethyl starch sodium, starch, dextrin etc., with 95% ethanol is that wetting agent is made 40 purpose wet granulars, in 60 ℃ of heated-air circulation ovens, dry, dried granule granulate adds an amount of Pulvis Talci, puts in the clean container and preserves, the drying process parameter: baking temperature is 60 ℃, and the time is 30 minutes; (6) encapsulated and packing: relative humidity less than 58% operation workshop condition under, filled capsules is sub-packed in (100/bottle) in the hard system plastic bottle; (7) control of product quality: adopt high-efficient liquid phase chromatogram technology, its effective component is monitored quantitative analysis, be about 2.1mg/g, guaranteed the reliability and stability of product quality as content of Danshensu.
Acute toxicity test is carried out in blood fat reducing liver-benefiting capsules sampling of the present invention, and sample is to acute oral LD female, white mice great and mighty or powerful
50All,, belong to nontoxic level material with acute toxicity median lethal dose(LD 50) toxicity grading greater than the 10000mg/kg body weight.
Blood fat reducing liver-benefiting capsules of the present invention, human body recommended dose are 2.25g/60kg every day, experimentize, and establish basic, normal, high three dosage groups, are equivalent to 5 times, 10 times and 30 times of human body recommended dose respectively.Specify the functional evaluation experiment of inspection body to show through country; per os gave animal sample after 30 days; promptly have blood fat reducing and liver-protective effect; serum cholesterol (TC) and serum levels of triglyceride (TG) that sample can suppress the high nutrient fodder rat of high fat raise; can obviously reduce carbon tetrachloride poisoning mice serum glutamate pyruvate transaminase GPT, glutamic oxaloacetic transaminase, GOT GOT, hepatic lesions obviously alleviates.The health care evaluation conclusion is the health care with the liver protecting and blood fat reducing, and suitable health care is taken good care of food and taken for a long time, is a kind of novel pure natural health-care.
Advantage of the present invention: the effective ingredient Ganoderma in the blood fat reducing liver-benefiting capsules formula for a product of the present invention, Radix Salviae Miltiorrhizae, Herb Gynostemmae Pentaphylli etc. all have the effect that improves liver SOD content and vigor.These components can realize the combination of hepatoprotective and two kinds of health cares of blood lipid regulation as a Chinese medicine compound, rather than only are to realize a function by several components wherein, and several components realize another function in addition.This existing product on market is unique.
Preparation method of the present invention combines the Asia multiple advanced technologies such as dynamic extraction, micropore fine filtration, spray drying of boiling, and compares with the traditional preparation process method, innovation is all arranged and improves.Adopt the Asia dynamic extraction technology of boiling, the static extract phase ratio with traditional not only makes extractive technique be further enhanced, and all improves significantly at aspects such as energy-saving and environmental protection, labor intensity and extraction time and efficient.The microporous filter technology that adopts, wherein the microporous pipe of Cai Yonging meets hygienic requirements, and use can be washed repeatedly according to wanting filtering particle size to select in the aperture, and occupation area of equipment is little.Spray drying technology makes material obtain drying in moment, reduced the loss of polysaccharide active component, volatile ingredient, and the quality of product is improved.Adopt high-efficient liquid phase chromatogram technology, its effective component is monitored quantitative analysis, be about 2.1mg/g, guaranteed the reliability and stability of product quality as content of Danshensu.
The specific embodiment
Embodiment 1
The experiment of blood fat reducing liver-benefiting capsules blood lipid regulation of the present invention effect
1. material
Sample and processing: sample is the product content thing, and brown ceramic powder during experiment, is mixed with each dosage with distilled water, and mixing is for examination.
Laboratory animal and testing conditions: laboratory animal, cleaning level SD male rat.Sense environmental conditions, 20～24 ℃ of temperature, relative humidity 40～65%.
High lipid food: 90.5% normal feedstuff, 2% cholesterol, 0.5% cholate, 7% Adeps Sus domestica.
2. method and result
The dosage design: three dosage groups and a high fat matched group are established in experiment.Basic, normal, high three dosage groups are respectively 0.19,0.38,1.13g/kg, are equivalent to 5 times, 10 times of people's recommended dose and 30 times (people's recommended amounts is 2.25g/ day) respectively.
Experimental technique: the rat feeding normal feedstuff is observed a week under experimental situation, gets tail blood, surveys the normal value of TC observation index.After the formal experiment beginning, each treated animal is got tail blood with high lipid food two weeks of feed, measures blood fat to determine whether to form hyperlipemia.After hyperlipemia model is set up, according to the TC level, carry out random packet again, per os is irritated stomach and is given sample, irritating the stomach amount is 1ml/100g, by a definite date two to around, high fat matched group is given the distilled water with volume, continues to give high lipid food, and regularly weigh in, in experiment beginning second to around, get tail blood, measure the every index of blood fat.
Interpretation of result: variance analysis.
The result
In conventional feed one week of normal feedstuff, recording the Serum TC normal value is 1.74 ± 0.25mmol/L.The feed high lipid food is after two weeks, and recording the Serum TC value is 3.69 ± 0.68mmol/L, with normal value have the highly significant difference (t=-19.014, p=1.89E-34), the experimental hyperlipemia in rats modelling.
After the hyperlipidemia rats modelling, observation the results are shown in Table 2 to the influence of sample to the hyperlipemia rat body weight, compares with last high, medium and low three the dosage group rat body weights of test and weight gain and high fat matched group before the test, the equal not statistically significant of difference (variance analysis, P＞0.05)
Table 2. sample is to the influence of hyperlipemia rat body weight
| Group | Number of animals (only) | Body weight (g) (X ± SD) | Weightening finish (g) (X ± SD) | |
| Before the test | The test end | |||
| High fat contrast 0.19g/kg 0.38g/kg 1.13g/kg | 10 10 10 10 | 324.2±20.1 327.4±9.2 324.1±14.8 321.0±17.5 | 365.7±16.4 367.1±12.1 360.7±18.3 359.1±13.8 | 41.5±21.8 39.7±17.1 36.6±19.0 38.1±19.3 |
| F P | 0.270 0.846 | 0.627 0.602 | 0.111 0.953 | |
After the experimental hyperlipemia in rats modelling, continue to give high lipid food, when testing second week of beginning, measure serum TC, the results are shown in Table 3, compare with high fat matched group, high, medium and low three dosage groups all can obviously reduce hyperlipidemia rats serum TC content, difference has significance, (q check, P＜0.05).
Table 3. sample is to the influence of hyperlipemia rat serum TC
| Group | Number of animals (only) | TC(mmol/L)(X±SD) | |
| Before the test | The test end | ||
| High fat contrast 0.19g/kg 0.38g/kg 1.13g/kg | 10 10 10 10 | 3.76±0.63 3.76±0.57 3.76±0.56 3.76±0.57 | 4.10±0.69 3.55±0.61 * 2.89±0.54 * 2.68±0.52 * |
| F P | 4.65E-05 1.000 | 11.918 1.44E-05 | |
Q check: compare * P＜0.05 with high fat matched group
After the experimental hyperlipemia in rats modelling, continue to give high lipid food, when testing second week of beginning, measure serum TG, the results are shown in Table 4, compare with high fat matched group, high, medium and low three dosage groups all can obviously reduce hyperlipidemia rats serum TG content, difference has significance, (q check, P＜0.05).
Table 4. sample is to the influence of hyperlipemia rat serum TG
| Group | Number of animals (only) | TG(mmol/L)(X±SD) | |
| Before the test | The test end | ||
| High fat contrast 0.19g/kg 0.38g/kg 1.13g/kg | 10 10 10 10 | 1.64±0.23 1.60±0.23 1.66±0.24 1.61±0.29 | 1.68±0.18 1.21±0.41 * 1.22±0.26 * 1.09±0.24 * |
| F P | 0.122 0.946 | 8.314 0.0002 | |
Q check: compare * P＜0.05 with high fat matched group
After the experimental hyperlipemia in rats modelling, continue to give high lipid food, in second week of experiment beginning, measure Serum HDL-C, the results are shown in Table 5, each dosage group rat blood serum HDL-C value and high fat control rats are relatively, the difference not statistically significant, (variance analysis, P＞0.05).
Table 5. sample is to the influence of hyperlipemia rat Serum HDL-C
| Group | Number of animals (only) | HDL-C(mg/dL)(X±SD) | |
| Before the test | The test end | ||
| High fat contrast | 10 | 60.39±13.92 | 73.09±12.83 |
| 0.19g/kg 038g/kg 1.13g/kg | 10 10 10 | 63.82±11.28 58.80±11.79 63.51±12.04 | 84.21±20.66 69.34±19.24 70.81±12.06 |
| F P | 0.394 0.758 | 1.643 0.197 |
This experimental result shows: compare with high fat control rats, high, medium and low dosage group all can obviously reduce hyperlipidemia rats serum cholesterol (TC) and serum levels of triglyceride (TG) content.
Conclusion: the present invention has the blood lipid regulation effect.
Embodiment 2
Blood fat reducing liver-benefiting capsules of the present invention is to the auxiliary protection function experiment of chemical liver injury
The sample character: sample contents is a brown granular.
The dosage design: sample human body recommended dose is 2.25g/60kg every day.This experiment is established basic, normal, high three.
0.19,0.38,1.13g/kg the dosage group:, other establishes liver injury model group and normal control group (giving distilled water).
Sample treatment: sample thief 0.19,0.38,1.13g adding distil water respectively make into even suspension to 20ml, are the test liquid of high, medium and low three dosage groups.
Laboratory animal: Kunming kind white mice, the 20-22 gram, female.
Give sample loading mode: irritate stomach, irritating the stomach volume is 0.4ml/20g.
Experimental technique and result:
Each dosage group is given sample, and matched group and model group are drunk distilled water, continuous 30 days.The 30th day each dosage group and model group CCL
4Contamination, dosage 24mg/kg, lumbar injection (i.p).The 31st day, 5 treated animals are plucked eyeball and got blood, and were centrifugal, get serum.Measure following biochemical indicator: serum glutamic pyruvic transminase (GPT), glutamic oxaloacetic transaminase, GOT (GOT), white/globulin ratio (A/G); And get liver and carry out histopathologic examination.Experimental result Spss software statistics.
1. body weight sees Table 6
Table 6. sample is to the influence of the weight of animals
| Group | Number of animals | Initial body weight | Mid-term body weight | Final body weight |
| Normal control CCL 4Dosage high dose in the model low dosage | 10 10 10 10 10 | 19±0.9 19±0.8 19±.0.9 19±0.8 19±0.9 | 27±1.7 28±1.7 27±1.2 27±1.7 28±1.4 | 37±1.5 37±1.0 34±2.3 36±3.8 36±2.3 |
By table 6 as seen, each dosage group and CCL of sample
4Model group is compared, difference that there are no significant.
2. biochemistry detection the results are shown in Table 7
Table 7. biochemistry detection result
| Group | Number of animals (only) | Glutamate pyruvate transaminase (IU/L) | Glutamic oxaloacetic transaminase, GOT (IU/L) | In vain/the globulin ratio |
| Normal control CCL 4Dosage high dose in the model low dosage | 10 10 10 10 10 | 62±11 * 831±133 826±162 486±104 * 383±67 * | 88±8 * 953±263 732±234 464±100 * 168±25 * | 1.77±0.52 1.92±0.50 1.82±0.52 2.02±0.85 1.85±0.53 |
* P＜0.05 and CCL
4Model group compares, (through variance analysis)
By table 7 as seen, the glutamate pyruvate transaminase of normal control group, glutamic oxaloacetic transaminase, GOT content are starkly lower than CCL
4There is significant difference in model group, and the model establishment is described.The glutamic oxaloacetic transaminase, GOT of the middle and high dosage group of sample, glutamate pyruvate transaminase all obviously reduce, with CCL
4Relatively all there is significant difference in model group.
3. pathological examination results sees Table 8
Table 8. pathologic finding total mark
| Group | Number of animals | Granular degeneration | Hydropic degeneration | The balloon degeneration | Steatosis | The endochylema cohesion | Necrocytosis | Inflammatory cell infiltration | Total points | Average mark |
| Contrast CCL 4Dosage high dose in the model low dosage | 10 10 10 10 10 | 15 12 12 13 14 | 12 16 12 12 11 | 0 14 10 9 7 | 0 10 8 7 4 | 0 34 26 24 24 | 0 34 27 24 24 | 2 14 13 11 10 | 29 134 108 100 94 | 2.9±0.9 * 13.4±3.1 10.8±2.3 10.0±3.0 9.4±2.6 * |
* P＜0.05 and CCL
4Model group is (through variance analysis) relatively
As shown in table 8, by check substantially and the microscopy result as seen, the pathology integration of normal control group is starkly lower than CCL
4There is significant difference in model group, and the model establishment is described.Sample high dose group and CCL
4Model control group is compared, and the pathology integration obviously descends, and has significant difference.
This experiment conclusion: the animal per os gave sample of the present invention after 30 days, had the protective effect to hepatic injury due to the chemicals.
Embodiment 3
The preparation method of blood fat reducing liver-benefiting capsules of the present invention, comprise extraction filtration, vacuum concentration, spray drying, the particulate preparation and dry, encapsulated and packing, control of product quality processing step of preparation raw material, medical material, it is characterized in that, (1) preparation raw material: by Ganoderma 17.64g, Radix Salviae Miltiorrhizae 17.64g, Fructus Lycii 11.766g, Herb Gynostemmae Pentaphylli 11.76g, Fructus Ligustri Lucidi 11.76g, Rhizoma Alismatis 17.64g, conduct preparation raw material after the prescription weighing of Tremella 11.80g; (2) extraction of medical material, filtration: get formula ratio and (separately Ganoderma is added 8 times of water gaging Asias boil dynamic extraction three times, each 1.5 hours, merge and filter, concentrate the back spray drying, Radix Salviae Miltiorrhizae adds 8 times of water gaging Asias boil dynamic extraction three times, each 1 hour, merge and filter, concentrate the back spray drying, then with Ganoderma, Radix Salviae Miltiorrhizae xeraphium and other Chinese medical concrete powder mixings) medical material, put in the multi-function extractor, add the about 30min of water logging bubble of 8 times of medical material amounts, boil dynamic extraction 3 times of employing Asia, each each 1.5 hours, micropore fine filtration is collected filtrate, puts in the clean container and preserves; (3) vacuum concentration: get above-mentioned filtrate, put and be concentrated into relative density in the vacuum concentrator and be 1.05～1.10 (60 ℃ of heat are surveyed), concentrated solution is put in the clean container and preserved, the vacuum concentration process parameter: vacuum is 0.04Mpa, temperature＜80 ℃; (4) spray drying: get vacuum concentration liquid, adopt the G-15 spray drying, make material obtain drying in moment, dry extract is put in the clean container and is preserved, drying parameter: 180 ℃ of intake air temperatures, 60 ℃ of air outlet temperature, 4 seconds drying times; (5) particulate preparation is with dry: get above-mentioned Chinese crude drug extract dry extract, add carboxymethyl starch sodium, starch, dextrin etc., with 95% ethanol is that wetting agent is made 40 purpose wet granulars, in 60 ℃ of heated-air circulation ovens, dry, dried granule granulate adds an amount of Pulvis Talci, puts in the clean container and preserves, the drying process parameter: baking temperature is 60 ℃, and the time is 30 minutes; (6) encapsulated and packing: relative humidity less than 58% operation workshop condition under, filled capsules is sub-packed in (100/bottle) in the hard system plastic bottle; (7) control of product quality: adopt high-efficient liquid phase chromatogram technology, its effective component is monitored, quantitative analysis is about 2.1mg/g as content of Danshensu, has guaranteed the reliability and stability of product quality.
Instructions about how to take medicine: obey every day 3 times, each 2, (the human body recommended dose is 2.25g/60kg, day).
Claims (2)
1. blood fat reducing liver-benefiting capsules, it is characterized in that it being that crude drug by following weight is made: Ganoderma 17.64～26.46g, Radix Salviae Miltiorrhizae 17.64～26.46g, Fructus Lycii 11.76～17.64g, Herb Gynostemmae Pentaphylli 11.76～17.64g, Fructus Ligustri Lucidi 11.76～17.64g, Rhizoma Alismatis 17.64～26.46g, Tremella 11.76～7.64g.
2. the preparation method of a blood fat reducing liver-benefiting capsules, it is characterized in that making: (1) preparation raw material: by Ganoderma 17.64～26.46g by following step, Radix Salviae Miltiorrhizae 17.64～26.46g, Fructus Lycii 11.76～17.64g, Herb Gynostemmae Pentaphylli 11.76～17.64g, Fructus Ligustri Lucidi 11.76～17.64g, Rhizoma Alismatis 17.64～26.46g, conduct preparation raw material after the weighing of Tremella 11.76～7.64g; (2) extraction of medical material, filtration: separately Ganoderma is added earlier 8 times of water gaging Asias boil dynamic extraction three times, each 1.5 hours, merge and filter, concentrate the back spray drying, Radix Salviae Miltiorrhizae adds 8 times of water gaging Asias boil dynamic extraction three times, each 1 hour, merge and filter, concentrate the back spray drying, then with Ganoderma, Radix Salviae Miltiorrhizae xeraphium and other Chinese medical concrete powder mixings, get above-mentioned weight medical material and put in the multi-function extractor, add the about 30min of water logging bubble of 8 times of medical material amounts, boil dynamic extraction 3 times of employing Asia, each each 1.5 hours, micropore fine filtration is collected filtrate, puts in the clean container and preserves; (3) vacuum concentration: get above-mentioned filtrate, put in the vacuum concentrator and to concentrate 60 ℃ of intermittent fever to survey relative densities be 1.05～1.10, concentrated solution is put in the clean container and preserved, the vacuum concentration process parameter: vacuum is 0.04Mpa, temperature＜80 ℃; (4) spray drying: get vacuum concentration liquid, adopt the G-15 spray drying, make material obtain drying in moment, dry extract is put in the clean container and is preserved, drying parameter: 180 ℃ of intake air temperatures, 60 ℃ of air outlet temperature, 4 seconds drying times; (5) particulate preparation is with dry: get above-mentioned Chinese crude drug extract dry extract, add carboxymethyl starch sodium, starch, dextrin etc., with 95% ethanol is that wetting agent is made 40 purpose wet granulars, in 60 ℃ of heated-air circulation ovens, dry, dried granule granulate adds an amount of Pulvis Talci, puts in the clean container and preserves, the drying process parameter: baking temperature is 60 ℃, and the time is 30 minutes; (6) encapsulated and packing: relative humidity less than 58% operation workshop condition under, filled capsules is sub-packed in the hard system plastic bottle; (7) control of product quality: adopt high-efficient liquid phase chromatogram technology, its effective component is monitored quantitative analysis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100977959A CN100340266C (en) | 2004-12-03 | 2004-12-03 | Jiangzhi capsule good for liver and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100977959A CN100340266C (en) | 2004-12-03 | 2004-12-03 | Jiangzhi capsule good for liver and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1781530A CN1781530A (en) | 2006-06-07 |
| CN100340266C true CN100340266C (en) | 2007-10-03 |
Family
ID=36772402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100977959A Expired - Fee Related CN100340266C (en) | 2004-12-03 | 2004-12-03 | Jiangzhi capsule good for liver and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100340266C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108618150A (en) * | 2018-06-12 | 2018-10-09 | 三明市园艺学会 | A kind of liver-protecting fat-dropping Capsules of health productions and its manufacture craft |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757265B (en) * | 2008-10-24 | 2012-03-21 | 常州善美药物研究开发中心有限公司 | Traditional Chinese medicine composition for treating persistent hepatitis and preparation method thereof |
| CN103202377A (en) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | Qinggan tea (for alcoholic liver and fatty liver) and making method thereof |
| CN103211058A (en) * | 2013-04-25 | 2013-07-24 | 福建永生活力生物工程有限公司 | Healthy tea granules for reducing blood fat in aided manner and preparation method thereof |
| CN105267488A (en) * | 2014-12-26 | 2016-01-27 | 完美（中国）有限公司 | Traditional Chinese medicine composition capable of assisting to reduce blood fat and protect liver and products thereof |
| CN108355021A (en) * | 2018-05-17 | 2018-08-03 | 福建省中医药研究院(福建省青草药开发服务中心） | A kind of improvement liver index Antrodia camphorata product and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371713A (en) * | 2002-03-25 | 2002-10-02 | 刘振顺 | Yilidan Chinese patent medicine |
| CN1371714A (en) * | 2002-03-25 | 2002-10-02 | 孟范英 | Powder medicine for treating liver disease |
-
2004
- 2004-12-03 CN CNB2004100977959A patent/CN100340266C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371713A (en) * | 2002-03-25 | 2002-10-02 | 刘振顺 | Yilidan Chinese patent medicine |
| CN1371714A (en) * | 2002-03-25 | 2002-10-02 | 孟范英 | Powder medicine for treating liver disease |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108618150A (en) * | 2018-06-12 | 2018-10-09 | 三明市园艺学会 | A kind of liver-protecting fat-dropping Capsules of health productions and its manufacture craft |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1781530A (en) | 2006-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230057438A (en) | Compositions of ginsenosides Rg3 and ginsenosides Rg5 and pharmaceutical uses thereof, including antitumor effects | |
| CN1275639C (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN106667915A (en) | Baicalin-aluminum dry suspension for treating pigling diarrhoea | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN100340266C (en) | Jiangzhi capsule good for liver and its preparing process | |
| CN100336537C (en) | Chinese medicinal composition for antifatigue and increasing immune power and its preparation method | |
| CN1283281C (en) | Medicinal composition containing wild jujube seed, lucid ganoderma and ginseng leaf and its preparing process and use | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN103463382B (en) | Traditional Chinese medicine for treating constipation, and preparation method and application thereof | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1218745C (en) | Health food for protecting liver and adjusting blood fat and method for preparing the same | |
| CN110721289A (en) | Preparation method of Renzhu stomach-invigorating granules | |
| CN115671222A (en) | Natural composite powder capable of improving type 2 diabetes and preparation method thereof | |
| CN103735621A (en) | Chinese medicinal composition with blood lipid reducing and immunity enhancing effects | |
| CN110664905A (en) | Traditional Chinese medicine preparation for expelling wind and clearing away cold and preparation method thereof | |
| CN1081924C (en) | Pharmaceutical composition comprising plant worms and muirapuama | |
| CN1857378A (en) | Compound wild kiwi tablet and its preparing method | |
| CN114533817A (en) | Composition for improving blood sugar and/or blood fat and application thereof | |
| CN1199683C (en) | Medicine combination for reducing blood fat and preventing senescence and its medicines | |
| CN1248715C (en) | Stomachic medication and preparation method | |
| CN100525804C (en) | Chinese traditional medicine compound preparations having a function of slimming | |
| CN110420258A (en) | A kind of cherokee rose root extract and its preparation method and application with establishing-Yang | |
| CN111388584A (en) | Composition for treating impotence and preparation method thereof | |
| CN109893603A (en) | It is a kind of to improve the composition of men's health, preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUO XIULIANG Free format text: FORMER OWNER: CHEN JIANWEI Effective date: 20130620 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Guo Xiuliang Inventor before: Chen Jianwei |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: CHEN JIANWEI TO: GUO XIULIANG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130620 Address after: 323700, Lane 53, West Street, Longquan, Zhejiang Patentee after: Guo Xiuliang Address before: 323700 Zhejiang province Longquan Jiangbin Road No. 101 Patentee before: Chen Jianwei |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071003 Termination date: 20161203 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |